Clinical Trial Search

Primary: Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana — 1807; 1894; 1194; 1787…

Primary: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 46; 45 Participants

Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human…

Primary: Evaluate the Safety and Tolerability of GT0918 and Select the RP2D for Future Clinical Trial Study. — 28; 29; 6; 12 Participants

Primary: Efficacy in Terms of Clinical Status Following Treatment With Pruxelutamide (GT0918) Compared to Placebo — 361; 357 Participants

Primary: Proportion of Tissue Eosinophil Responders at Week 24 — 77; 4 Participants — p=<0.0001

Primary: Concentration of Plasma Free Fatty Acids (FFA, mmol/L) — 0.47; 0.51 mmol/L

Primary: Change in Pain From Baseline as Assessed by the Numeric Pain Rating Scale (NPRS) Score — -2.25 score on a scale

Primary: Establish Noninferiority of the Single Dose Antibiotic Administration to the Multi-dose Antibiotic Administration. — 1; 1 Participants

Primary: Proportion of Subjects Who Achieve a Peak Esophageal Intraepithelial Count of ≤6 Eosinophils/Hpf at Week 24 — 86; 80; 10 Participants — p=<0.0001

Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74

Primary: Change in Mean Arterial Pressure (MAP) From the Baseline MAP — 76.3; 76.9; 73.5; 76.3 mm Hg — p=<0.001

Primary: Number of Dose Limiting Toxicities of Selinexor — 0; 4; 1; 2 Participants

Primary: Dose-limiting-toxicities (DLTs) (Phase 1) — 0; 0; 0; 0 Participants

Primary: Time to Optimal Insulin Dose — 56; 15 days — p=0.006